AGENIX SUCCESSFULLY COMPLETES PHASE IA BLOOD CLOT TRIAL.

Brisbane-based biotechnology company Agenix Limited [ASX:AGX, NASDAQ: AGXLY] has successfully completed the patient- treatment component of its phase Ia trial for ThromboView, the company's blood clot-detection technology.

ThromboView has been injected into 32 patients at Royal Brisbane Hospital under the supervision of Dr David Macfarlane from the hospital's Department of Nuclear Medicine.

Dr Macfarlane said: "The trial has gone extremely well and we will finalize the results in the coming months." The trial was designed to test the safety profile of ThromboView in healthy volunteers.

"The results so far are on track," said managing director of Agenix, Don Home. "All four dose levels of ThromboView were well-tolerated and there were no serious side effects. The Phase Ia report will be part of a package for an Investigational New Drug (IND) application with the US Food & Drug Administration (USFDA)."

Further testing of ThromboView will proceed under the IND.

"The world desperately needs a better method to detect blood clots," said Home. "Currently, 50% of blood clots are detected in autopsy."

Details of the impact of blood clots worldwide:

60,000 people die from blood clots in the United States each year, making blood clots a more common cause of death than breast cancer.

60,000 people die from blood clots in Europe each year.

Two million people in both Europe and the USA suffer deep vein thrombosis each year.

Thromboembolism is the third most common cause of cardiovascular death after heart attack and stroke.

It is estimated up to 10,000 people die of undetected blood clots each year in Australia.

There are approximately 33,000 cases of Deep Vein Thrombosis each year in Australia.

There are approximately 4,200 cases of pulmonary embolism (clots in the lungs) each year in Australia.

ThromboView uses a clot-binding monoclonal antibody attached to a radiolabel. Following injection of a few millilitres of ThromboView into a patient with a suspected blood clot, the antibody will flow through a person's body and bind to any existing blood clots. The resulting "hotspots", indicating the presence of the blood clot, are detected by an imaging camera.

Agenix Limited [ASX:AGX, NASDAQ: AGXLY] is a listed company based in Brisbane, Australia. It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its wholly-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally-integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead candidate is its high-technology ThromboView=E2 blood clot-imaging project, which is currently undergoing human trials. ThromboView uses radiolabelled antibodies to locate blood clots in the body. It could revolutionise the US $3 billion global clot diagnostic imaging market. Agenix employs 190 staff and sells its products to more than 50 countries. ThromboView is a registered trademark of AGEN Biomedical.

For more information, visit http://www.agenix.net.